Visual Outcomes after Implantation of Lucidis EDOF IOL.

Purpose: To evaluate the visual performance and clinical outcomes after implantation of Lucidis EDOF IOL following cataract surgery.

Design: In this retrospective study, medical records from all enrolled patients were analyzed, and the following information was extracted retrospectively over 3 months following surgery.

Materials And Methods: We reviewed retrospectively 181 eyes of 98 patients, who underwent cataract surgery with Lucidis extended depth of focus IOL.

Influence of Posterior Corneal Asphericity On Power Calculation Error After Laser In Situ Keratomileusis or Photorefractive Keratectomy for Myopia.

Objectives: To assess the impact of posterior corneal asphericity on postoperative calculation error using the Haigis-L and the Barrett formulas for eyes after laser in situ keratomileusis or photorefractive keratectomy (PRK).

Methods: We assessed the mean absolute error (MAE) of two power calculation formulas, Barrett true-K and Haigis-L formulas, in a retrospective analysis of 34 eyes of 34 patients who underwent cataract surgery. We performed a regression analysis between corneal parameters (anterior and posterior Q values, Kmax, K1, and K2) and the MAE of each formula.

Posterior Corneal Asphericity Effect on Postoperative Astigmatism after EDOF Intraocular Lens Implantation in Cataract Patients.

Aim: To assess the impact of posterior corneal asphericity on postoperative astigmatism.

Methods: We included retrospectively 70 eyes of 70 patients that underwent cataract surgery. We included data of the value, , 1, 2, astigmatism AL, and ACD.

Influence of Posterior Corneal Asphericity on Refractive Error of SRK-T and Barrett Formulas for Lucidis IOL.

Purpose: To evaluate the influence of posterior corneal asphericity on the refractive error using SRK-T and Barrett formulas for the intraocular lens (IOL) power calculation for Lucidis Extended Depth of Focus (EDOF) IOL.

Setting: This study was carried out at a tertiary ophthalmology center in Geneva, Switzerland.

Design: A retrospective study.

Span poly-L-arginine nanoparticles are efficient non-viral vectors for PRPF31 gene delivery: An approach of gene therapy to treat retinitis pigmentosa.

Retinitis pigmentosa (RP) is the most common cause of inherited blindness in adults. Mutations in the PRPF31 gene produce autosomal dominant RP (adRP). To date there are no effective treatments for this disease.